Nippon Shinyaku Co., Ltd. (TYO: 4516)
Japan
· Delayed Price · Currency is JPY 4,185.00
+49.00 (1.18%)
Dec 16, 2024, 3:45 PM JST
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 40.20B JPY in the quarter ending September 30, 2024, with 10.74% growth. This brings the company's revenue in the last twelve months to 154.27B, up 5.41% year-over-year. In the fiscal year ending March 31, 2024, Nippon Shinyaku had annual revenue of 148.26B with 2.83% growth.
Revenue (ttm)
154.27B
Revenue Growth
+5.41%
P/S Ratio
1.83
Revenue / Employee
69.71M
Employees
2,213
Market Cap
282.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
| Mar 31, 2020 | 116.64B | 1.92B | 1.67% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNippon Shinyaku News
- 3 months ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 3 months ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 3 months ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga